Opinion

Video

Endocrine Sensitivity and the Prognostic and Clinical Implications

Dr. Gandhi and Dr. Clifton explore the prevalence and mechanisms of resistance to first-line endocrine therapy combined with CDK4/6 inhibitors in hormone receptor–positive/HER2-negative (HR+/HER2–) breast cancer.

Video content above is prompted by the following:

  • What proportion of patients with HR+/HER2– breast cancer experience resistance to first-line endocrine therapy plus CDK4/6 inhibitor?
  • What are some of the mechanisms of resistance that can emerge following endocrine therapy and CDK4/6 inhibitors in HR+/HER2– breast cancer?
  • How you think about endocrine resistance in the post-CDK4/6 setting? What signals—clinical, molecular, or otherwise—influence your treatment sequencing decisions?
  • How does treatment resistance after first-line treatment create challenges in selecting second-line therapies?
Related Videos
Werutsky
5 experts are featured in this series
5 experts are featured in this series
2 expert is featured in this series.